Appello Completes $10.5 Million Series A Financing

Appello Pharmaceuticals, Inc. (“Appello” or “Company”) today announced the completion of a $10.5 million Series A financing led by Deerfield Management and Mountain Group Partners (“MGP”). This initial investment will support the development of novel positive allosteric modulators (“PAMs”) of the metabotropic glutamate receptor subtype 4 (“mGlu4”) as an innovative new treatment for Parkinson’s disease.

Read the full press release: